



ASX ANNOUNCEMENT

17 DECEMBER 2021

## SUCCESSFUL COMPLETION OF 2<sup>ND</sup> DOSE COHORT IN CLTX CAR T PHASE 1 TRIAL

- 2<sup>nd</sup> dose cohort in the CLTX CAR T cell therapy phase 1 clinical trial completed at City of Hope near Los Angeles
- All patients have advanced past the 28 day follow up period with no dose limiting toxicities
- This 2<sup>nd</sup> dose cohort introduced dual routes of CLTX CAR T administration at a total dose of  $88 \times 10^6$  CLTX CAR T cells
- The phase 1 clinical trial will now advance to the 3<sup>rd</sup> dose cohort with dual routes of administration at a total dose of  $220 \times 10^6$  CLTX CAR T cells

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to announce the successful completion of the 2<sup>nd</sup> dose cohort in the CLTX CAR T phase 1 dose escalation study at the City of Hope, a world-renowned cancer research and treatment organization near Los Angeles.

All patients in the 2<sup>nd</sup> dose cohort were dosed with a total dose of  $88 \times 10^6$  CLTX CAR T cells (double that used in the first dose cohort) and have now advanced past the 28 day follow up period without experiencing any dose limiting toxicities.

The successful completion of this 2<sup>nd</sup> patient cohort is a significant milestone for CLTX CAR T cell therapy as the 2<sup>nd</sup> dose cohort introduced dual routes (intraventricular and intratumoral) of CLTX CAR T administration.

The study now advances to the 3<sup>rd</sup> dose cohort, which will administer CLTX CAR T cells to patients through the dual routes of administration at an increased total dose of  $220 \times 10^6$  CLTX CAR T cells.

*“Chimeric is incredibly pleased to have reached this important milestone with our CLTX CAR T cell therapy. Demonstrating safety with dual routes of administration (ICT and ICV) at this 2<sup>nd</sup> CLTX CAR T dose level is very encouraging. We now look forward to further advancing the development of CLTX CAR T as we enter the 3<sup>rd</sup> dose level in the trial,”* said Jennifer Chow, Chimeric Therapeutics Chief Executive Officer.




### About the CLTX CAR T (CHM1101) Clinical Trial:

The CLTX CAR T phase 1 clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022. The design is a single arm trial in patients with MMP2+ recurrent or progressive glioblastoma.

The primary endpoints of the trial are to assess the safety of CLTX CAR T cells, determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan. Secondary endpoints include bioactivity and efficacy measures.

The trial is designed with 4 dose levels ranging from  $44 \times 10^6$  to  $440 \times 10^6$  CLTX CAR T cells and studies both single and dual routes of administration of cells. Dose level 1 was completed with no dose limiting toxicities in April 2021.



Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

### ABOUT CHLOROTOXIN CAR T

Chlorotoxin CAR T (CLTX CAR T) cell therapy is a first and best in class CAR T cell therapy that has the potential to address the high unmet medical need of patients with recurrent/ progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.

CLTX CAR T cell therapy uniquely utilizes chlorotoxin (CLTX), a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor (CAR). CLTX and CLTX CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13.

In preclinical models, CLTX CAR T cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.



## ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and the ASX leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma. A 2<sup>nd</sup> CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Recently Chimeric announced the addition of the CORE-NK platform, a clinically validated, off the shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials to begin in 2023 in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

## CONTACT

### Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper  
Executive Chairman  
Chimeric Therapeutics  
T: + 61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)